Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 7/2016

30.04.2016 | Review Article

Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications

verfasst von: Irini Chatziralli, George Theodossiadis, Paraskevi Xanthopoulou, Michael Miligkos, Sobha Sivaprasad, Panagiotis Theodossiadis

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to provide a meta-analysis of the factors affecting vitreomacular traction (VMT) resolution after ocriplasmin use. A comprehensive systematic review of the complications after ocriplasmin use for VMT and macular hole was also done.

Methods

A literature search in PubMed was performed for studies about ocriplasmin published before 30 June 2015. Then a meta-analysis of the factors affecting the VMT resolution after ocriplasmin use was done, providing the pooled odds ratios for each factor and 95 % confidence intervals (CIs). We also described the potential adverse events after ocriplasmin use in a systematic review.

Results

A total of 194 abstracts were screened and 19 eligible studies were included in the meta-analysis. Age <65 years, female gender, vitreomacular adhesion diameter <1500 μm, phakic lens status and epiretinal membrane absence were found as positive predictive factors for VMT resolution, while macular hole size <250 μm was significantly associated with macular hole closure at the meta-analytical level. Various complications after ocriplasmin use were reported by frequency, including mainly vitreous floaters, photopsias, visual acuity decrease, ellipsoid zone changes, subretinal fluid development, enlargement of macular hole, anterior segment changes and electroretinogram alterations. It has to be noted that significant methodological weaknesses were identified, such as the absence of control groups or lack of transparency in the recruitment process and the examination procedure.

Conclusions

It is important to carefully select patients for ocriplasmin injection, taking into account the various predictive factors for VMT resolution. Patients should be informed about the potential adverse events of ocriplasmin, although they mainly seemed to be transient and usually mild/moderate in severity, suggesting that ocriplasmin is a safe and effective new treatment alternative for VMT and macular hole. However, due to the limited study quality, the uncertainty concerning the efficacy of this new approach is increased.
Literatur
2.
Zurück zum Zitat Johnson MW (2005) Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc 103:537–567PubMedPubMedCentral Johnson MW (2005) Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc 103:537–567PubMedPubMedCentral
3.
Zurück zum Zitat Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P (2013) The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120:2611–2619CrossRefPubMed Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P (2013) The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology 120:2611–2619CrossRefPubMed
4.
Zurück zum Zitat Stalmans P, Duker JS, Kaiser PK, Heier JS, Dugel PU, Gandorfer A, Sebag J, Haller JA (2013) Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina 33:2003–2011CrossRefPubMed Stalmans P, Duker JS, Kaiser PK, Heier JS, Dugel PU, Gandorfer A, Sebag J, Haller JA (2013) Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina 33:2003–2011CrossRefPubMed
5.
Zurück zum Zitat John VJ, Flynn HW Jr, Smiddy WE, Carver A, Leonard R, Tabandeh H, Boyer DS (2014) Clinical course of vitreomacular adhesion managed by initial observation. Retina 34:442–446CrossRefPubMed John VJ, Flynn HW Jr, Smiddy WE, Carver A, Leonard R, Tabandeh H, Boyer DS (2014) Clinical course of vitreomacular adhesion managed by initial observation. Retina 34:442–446CrossRefPubMed
6.
Zurück zum Zitat Dimopoulos S, Bartz-Schmidt KU, Gelisken F, Januschowski K, Ziemssen F (2015) Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy? Br J Ophthalmol 99:350–353CrossRefPubMed Dimopoulos S, Bartz-Schmidt KU, Gelisken F, Januschowski K, Ziemssen F (2015) Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy? Br J Ophthalmol 99:350–353CrossRefPubMed
7.
Zurück zum Zitat Mester V, Kuhn F (2000) Internal limiting membrane removal in the management of full-thickness macular holes. Am J Ophthalmol 129:769–777CrossRefPubMed Mester V, Kuhn F (2000) Internal limiting membrane removal in the management of full-thickness macular holes. Am J Ophthalmol 129:769–777CrossRefPubMed
8.
Zurück zum Zitat Kuppermann BD (2012) Ocriplasmin for pharmacologic vitreolysis. Retina 32:225–228CrossRef Kuppermann BD (2012) Ocriplasmin for pharmacologic vitreolysis. Retina 32:225–228CrossRef
9.
Zurück zum Zitat Syed YY, Dhillon S (2013) Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion. Drugs 73:1617–1625CrossRefPubMed Syed YY, Dhillon S (2013) Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion. Drugs 73:1617–1625CrossRefPubMed
10.
Zurück zum Zitat Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA, MIVI-TRUST Study Group (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615CrossRefPubMed Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, Haller JA, MIVI-TRUST Study Group (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:606–615CrossRefPubMed
11.
Zurück zum Zitat Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, Kampik A, Jaffe GJ, Toth CA, MIVI-TRUST Study Group (2015) Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 122:117–122CrossRefPubMed Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, Kampik A, Jaffe GJ, Toth CA, MIVI-TRUST Study Group (2015) Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 122:117–122CrossRefPubMed
12.
Zurück zum Zitat Trikalinos TA, Trow P, Schmid CH (2013) Simulation-Based Comparison of Methods for Meta-Analysis of Proportions and Rates. Methods Research Report. (Prepared by the Tufts Medical Center Evidence-based Practice Center under Contract No. 290-2007-10055-I.) AHRQ Publication No. 13(14)-EHC084-EF. Rockville, MD: Agency for Healthcare Research and Quality www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed 09 Sep 2015. Trikalinos TA, Trow P, Schmid CH (2013) Simulation-Based Comparison of Methods for Meta-Analysis of Proportions and Rates. Methods Research Report. (Prepared by the Tufts Medical Center Evidence-based Practice Center under Contract No. 290-2007-10055-I.) AHRQ Publication No. 13(14)-EHC084-EF. Rockville, MD: Agency for Healthcare Research and Quality www.​effectivehealthc​are.​ahrq.​gov/​reports/​final.​cfm. Accessed 09 Sep 2015.
13.
Zurück zum Zitat Louis TA (1991) Using empirical Bayes methods in biopharmaceutical research. Stat Med 10:811–827CrossRefPubMed Louis TA (1991) Using empirical Bayes methods in biopharmaceutical research. Stat Med 10:811–827CrossRefPubMed
15.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:1–34CrossRef Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:1–34CrossRef
16.
Zurück zum Zitat Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefPubMed Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefPubMed
17.
Zurück zum Zitat Varma R, Haller JA, Kaiser PK (2015) Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. JAMA Ophthalmol 133:997–1004CrossRefPubMed Varma R, Haller JA, Kaiser PK (2015) Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials. JAMA Ophthalmol 133:997–1004CrossRefPubMed
18.
Zurück zum Zitat Gandorfer A, Benz MS, Haller JA, Stalmans P, Pakola SJ, Girach A, Kampik A, Toth CA, Jaffe GJ, MIVI-TRUST Study Group (2015) Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. Retina 35:1151–1157CrossRefPubMed Gandorfer A, Benz MS, Haller JA, Stalmans P, Pakola SJ, Girach A, Kampik A, Toth CA, Jaffe GJ, MIVI-TRUST Study Group (2015) Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. Retina 35:1151–1157CrossRefPubMed
19.
Zurück zum Zitat de Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Feron E, Pakola S, Kampik A (2009) Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 116:1349–1355CrossRefPubMed de Smet MD, Gandorfer A, Stalmans P, Veckeneer M, Feron E, Pakola S, Kampik A (2009) Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 116:1349–1355CrossRefPubMed
20.
Zurück zum Zitat Stalmans P, Delaey C, de Smet MD, van Dijkman E, Pakola S (2010) Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina 30:1122–1127CrossRefPubMed Stalmans P, Delaey C, de Smet MD, van Dijkman E, Pakola S (2010) Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina 30:1122–1127CrossRefPubMed
21.
22.
Zurück zum Zitat Johnson MW, Fahim AT (2015) Understanding the adverse effects of ocriplasmin -reply. JAMA Ophthalmol 133:230CrossRefPubMed Johnson MW, Fahim AT (2015) Understanding the adverse effects of ocriplasmin -reply. JAMA Ophthalmol 133:230CrossRefPubMed
23.
Zurück zum Zitat Tibbetts MD, Reichel E, Witkin AJ (2015) Understanding the adverse effects of ocriplasmin - reply. JAMA Ophthalmol 133:229–230CrossRefPubMed Tibbetts MD, Reichel E, Witkin AJ (2015) Understanding the adverse effects of ocriplasmin - reply. JAMA Ophthalmol 133:229–230CrossRefPubMed
24.
Zurück zum Zitat Hong J, Deng SX, Xu J (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:2053PubMed Hong J, Deng SX, Xu J (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:2053PubMed
25.
Zurück zum Zitat Rao RC, Dlouhy BJ (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:2053PubMed Rao RC, Dlouhy BJ (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:2053PubMed
26.
Zurück zum Zitat Huang J, Wen D, Wang Q (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:2052–2053CrossRefPubMed Huang J, Wen D, Wang Q (2012) Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 367:2052–2053CrossRefPubMed
27.
Zurück zum Zitat Novack RL, Staurenghi G, Girach A, Narendran N, Tolentino M (2015) Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration. Ophthalmology 122:796–802CrossRefPubMed Novack RL, Staurenghi G, Girach A, Narendran N, Tolentino M (2015) Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration. Ophthalmology 122:796–802CrossRefPubMed
28.
Zurück zum Zitat Maier M, Abraham S, Frank C, Feucht N, Lohmann CP (2015) Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole: First clinical experiences. Ophthalmologe 112:990–994CrossRefPubMed Maier M, Abraham S, Frank C, Feucht N, Lohmann CP (2015) Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole: First clinical experiences. Ophthalmologe 112:990–994CrossRefPubMed
29.
Zurück zum Zitat Steel DH, Sandinha MT, White K (2015) The Plane of Vitreoretinal Separation and Results of Vitrectomy Surgery in Patients Given Ocriplasmin for Idiopathic Macular Hole. Invest Ophthalmol Vis Sci 56:4038–4044CrossRefPubMed Steel DH, Sandinha MT, White K (2015) The Plane of Vitreoretinal Separation and Results of Vitrectomy Surgery in Patients Given Ocriplasmin for Idiopathic Macular Hole. Invest Ophthalmol Vis Sci 56:4038–4044CrossRefPubMed
30.
Zurück zum Zitat Quezada-Ruiz C, Pieramici DJ, Nasir M, Rabena M, Steinle N, Castellarin AA, Dhoot D, Couvillion S, See RF, Avery RL (2015) Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole. Retina 35:1144–1150CrossRefPubMed Quezada-Ruiz C, Pieramici DJ, Nasir M, Rabena M, Steinle N, Castellarin AA, Dhoot D, Couvillion S, See RF, Avery RL (2015) Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole. Retina 35:1144–1150CrossRefPubMed
31.
Zurück zum Zitat Chatziralli I, Theodossiadis G, Parikakis E, Datseris I, Theodossiadis P (2016) Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Graefes Arch Clin Exp Ophthalmol 254:223–233CrossRefPubMed Chatziralli I, Theodossiadis G, Parikakis E, Datseris I, Theodossiadis P (2016) Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study. Graefes Arch Clin Exp Ophthalmol 254:223–233CrossRefPubMed
32.
Zurück zum Zitat Reiss B, Smithen L, Mansour S (2015) Transient vision loss after ocriplasmin injection. Retina 35:1107–1110CrossRefPubMed Reiss B, Smithen L, Mansour S (2015) Transient vision loss after ocriplasmin injection. Retina 35:1107–1110CrossRefPubMed
33.
Zurück zum Zitat Willekens K, Abegão Pinto L, Vandewalle E, Stalmans I, Stalmans P (2015) Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology. Retina 35:1135–1143CrossRefPubMed Willekens K, Abegão Pinto L, Vandewalle E, Stalmans I, Stalmans P (2015) Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology. Retina 35:1135–1143CrossRefPubMed
34.
Zurück zum Zitat Meyer JC, Shah GK, Blinder KJ, Waheed NK, Reichel E, Stalmans P, Singer M, Tewari A (2015) Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 46:209–216CrossRefPubMed Meyer JC, Shah GK, Blinder KJ, Waheed NK, Reichel E, Stalmans P, Singer M, Tewari A (2015) Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 46:209–216CrossRefPubMed
35.
Zurück zum Zitat Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C (2015) Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol 159:861–867CrossRefPubMed Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C (2015) Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol 159:861–867CrossRefPubMed
36.
Zurück zum Zitat Hager A, Seibel I, Riechardt A, Rehak M, Joussen AM (2015) Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes? Br J Ophthalmol 99:635–638CrossRefPubMed Hager A, Seibel I, Riechardt A, Rehak M, Joussen AM (2015) Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes? Br J Ophthalmol 99:635–638CrossRefPubMed
37.
Zurück zum Zitat Warrow DJ, Lai MM, Patel A, Raevis J, Berinstein DM (2015) Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. Am J Ophthalmol 159:20–30CrossRefPubMed Warrow DJ, Lai MM, Patel A, Raevis J, Berinstein DM (2015) Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. Am J Ophthalmol 159:20–30CrossRefPubMed
38.
Zurück zum Zitat Chin EK, Almeida DR, Sohn EH, Boldt HC, Mahajan VB, Gehrs KM, Russell SR, Folk JC (2014) Incomplete vitreomacular traction release using intravitreal ocriplasmin. Case Rep Ophthalmol 5:455–462CrossRefPubMedPubMedCentral Chin EK, Almeida DR, Sohn EH, Boldt HC, Mahajan VB, Gehrs KM, Russell SR, Folk JC (2014) Incomplete vitreomacular traction release using intravitreal ocriplasmin. Case Rep Ophthalmol 5:455–462CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Itoh Y, Kaiser PK, Singh RP, Srivastava SK, Ehlers JP (2014) Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography. Ophthalmology 121:2506–2507CrossRefPubMedPubMedCentral Itoh Y, Kaiser PK, Singh RP, Srivastava SK, Ehlers JP (2014) Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography. Ophthalmology 121:2506–2507CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Miller JB, Kim LA, Wu DM, Vavvas DG, Eliott D, Husain D (2014) Ocriplasmin for treatment of stage 2 macular holes: early clinical results. Ophthalmic Surg Lasers Imaging Retina 45:293–297CrossRefPubMedPubMedCentral Miller JB, Kim LA, Wu DM, Vavvas DG, Eliott D, Husain D (2014) Ocriplasmin for treatment of stage 2 macular holes: early clinical results. Ophthalmic Surg Lasers Imaging Retina 45:293–297CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Knudsen VM, Kozak I (2014) A retrospective study of a single practice use of ocriplasmin in the treatment of vitreomacular traction. Saudi J Ophthalmol 28:139–144CrossRefPubMedPubMedCentral Knudsen VM, Kozak I (2014) A retrospective study of a single practice use of ocriplasmin in the treatment of vitreomacular traction. Saudi J Ophthalmol 28:139–144CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Lommatzsch AP, Gutfleisch M, Dietzel M, Heimes B, Spital G, Böhme M, Bornfeld N, Pauleikhoff D (2014) Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin. Klin Monbl Augenheilkd 231:909–914CrossRefPubMed Lommatzsch AP, Gutfleisch M, Dietzel M, Heimes B, Spital G, Böhme M, Bornfeld N, Pauleikhoff D (2014) Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin. Klin Monbl Augenheilkd 231:909–914CrossRefPubMed
43.
Zurück zum Zitat Singh RP, Li A, Bedi R, Srivastava S, Sears JE, Ehlers JP, Schachat AP, Kaiser PK (2014) Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 98:356–360CrossRefPubMed Singh RP, Li A, Bedi R, Srivastava S, Sears JE, Ehlers JP, Schachat AP, Kaiser PK (2014) Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 98:356–360CrossRefPubMed
44.
Zurück zum Zitat Kim BT, Schwartz SG, Smiddy WE, Doshi RR, Kovach JL, Berrocal AM, Moshfeghi AA, Fortun JA (2013) Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 44:334–343CrossRefPubMed Kim BT, Schwartz SG, Smiddy WE, Doshi RR, Kovach JL, Berrocal AM, Moshfeghi AA, Fortun JA (2013) Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 44:334–343CrossRefPubMed
45.
Zurück zum Zitat Casswell E, Fernandez-Sanz G, Mitry D, Luk S, Zakir R (2014) Macular Hole Progression following Ocriplasmin Intravitreal Injection. Case Rep Ophthalmol Med 2014:403461PubMedPubMedCentral Casswell E, Fernandez-Sanz G, Mitry D, Luk S, Zakir R (2014) Macular Hole Progression following Ocriplasmin Intravitreal Injection. Case Rep Ophthalmol Med 2014:403461PubMedPubMedCentral
46.
47.
Zurück zum Zitat Silva RA, Moshfeghi DM, Leng T (2014) Retinal breaks due to intravitreal ocriplasmin. Clin Ophthalmol 8:1591–1594PubMedPubMedCentral Silva RA, Moshfeghi DM, Leng T (2014) Retinal breaks due to intravitreal ocriplasmin. Clin Ophthalmol 8:1591–1594PubMedPubMedCentral
48.
Zurück zum Zitat Keller J, Haynes RJ (2015) Zonular Dehiscence at the Time of Combined Vitrectomy and Cataract Surgery After Intravitreal Ocriplasmin Injection. JAMA Ophthalmol 133:1091–1092CrossRefPubMed Keller J, Haynes RJ (2015) Zonular Dehiscence at the Time of Combined Vitrectomy and Cataract Surgery After Intravitreal Ocriplasmin Injection. JAMA Ophthalmol 133:1091–1092CrossRefPubMed
49.
Zurück zum Zitat Barteselli G, Carini E, Invernizzi A, Ratiglia R, Viola F (2016) Early panretinal abnormalities on fundus autofluorescence and spectral domain optical coherence tomography after intravitreal ocriplasmin. Acta Ophthalmol 94:160–162CrossRef Barteselli G, Carini E, Invernizzi A, Ratiglia R, Viola F (2016) Early panretinal abnormalities on fundus autofluorescence and spectral domain optical coherence tomography after intravitreal ocriplasmin. Acta Ophthalmol 94:160–162CrossRef
50.
Zurück zum Zitat Han IC, Scott AW (2015) Sterile endophthalmitis after intravitreal ocriplasmin injection: report of a single case. Retin Cases Brief Rep 9:242–244CrossRefPubMed Han IC, Scott AW (2015) Sterile endophthalmitis after intravitreal ocriplasmin injection: report of a single case. Retin Cases Brief Rep 9:242–244CrossRefPubMed
51.
Zurück zum Zitat Chuo JY, Lee TY, Hollands H, Morris AH, Reyes RC, Rossiter JD, Meredith SP, Maberley DA (2006) Risk factors for posterior vitreous detachment: a case–control study. Am J Ophthalmol 142:931–937CrossRefPubMed Chuo JY, Lee TY, Hollands H, Morris AH, Reyes RC, Rossiter JD, Meredith SP, Maberley DA (2006) Risk factors for posterior vitreous detachment: a case–control study. Am J Ophthalmol 142:931–937CrossRefPubMed
52.
Zurück zum Zitat Hilford D, Hilford M, Mathew A, Polkinghorne PJ (2009) Posterior vitreous detachment following cataract surgery. Eye 23:1388–1392CrossRefPubMed Hilford D, Hilford M, Mathew A, Polkinghorne PJ (2009) Posterior vitreous detachment following cataract surgery. Eye 23:1388–1392CrossRefPubMed
53.
Zurück zum Zitat Reiss B, Smithen L, Mansour S (2015) Acute vision loss after ocriplasmin use. Retin Cases Brief Rep 9:168–169CrossRefPubMed Reiss B, Smithen L, Mansour S (2015) Acute vision loss after ocriplasmin use. Retin Cases Brief Rep 9:168–169CrossRefPubMed
54.
Zurück zum Zitat Fahim AT, Khan NW, Johnson MW (2014) Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol 132:484–486CrossRefPubMed Fahim AT, Khan NW, Johnson MW (2014) Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol 132:484–486CrossRefPubMed
55.
Zurück zum Zitat Freund KB, Shah SA, Shah VP (2013) Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye 27:773–774CrossRefPubMedPubMedCentral Freund KB, Shah SA, Shah VP (2013) Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye 27:773–774CrossRefPubMedPubMedCentral
56.
Zurück zum Zitat DaCosta J, Younis S (2014) Transient visual loss and delayed resolution of vitreomacular traction after intravitreal ocriplasmin. Drug Healthc Patient Saf 6:175–178CrossRefPubMedPubMedCentral DaCosta J, Younis S (2014) Transient visual loss and delayed resolution of vitreomacular traction after intravitreal ocriplasmin. Drug Healthc Patient Saf 6:175–178CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Quezada Ruiz C, Pieramici DJ, Nasir M, Rabena M, Avery RL (2015) Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection. Retin Cases Brief Rep 9:145–148CrossRefPubMed Quezada Ruiz C, Pieramici DJ, Nasir M, Rabena M, Avery RL (2015) Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection. Retin Cases Brief Rep 9:145–148CrossRefPubMed
59.
Zurück zum Zitat de Smet MD, Jonckx B, Vanhove M, van Calster J, Stalmans P, Stassen J (2010) Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 53:8208–8213CrossRef de Smet MD, Jonckx B, Vanhove M, van Calster J, Stalmans P, Stassen J (2010) Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 53:8208–8213CrossRef
60.
Zurück zum Zitat Stalmans P, Girach A (2013) Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial. Invest Ophthalmol Vis Sci 54:6620–6627CrossRefPubMed Stalmans P, Girach A (2013) Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial. Invest Ophthalmol Vis Sci 54:6620–6627CrossRefPubMed
61.
Zurück zum Zitat Thanos A, Hernandez-Siman J, Marra KV, Arroyo JG (2014) Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection. Retin Cases Brief Rep 8:330–332CrossRefPubMed Thanos A, Hernandez-Siman J, Marra KV, Arroyo JG (2014) Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection. Retin Cases Brief Rep 8:330–332CrossRefPubMed
62.
Zurück zum Zitat Tibbetts MD, Reichel E, Witkin AJ (2014) Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography. JAMA Ophthalmol 132:487–490CrossRefPubMed Tibbetts MD, Reichel E, Witkin AJ (2014) Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography. JAMA Ophthalmol 132:487–490CrossRefPubMed
63.
Zurück zum Zitat Ziemssen F, Bartz-Schmidt KU, Dimopoulos S (2016) Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when? Graefes Arch Clin Exp Ophthalmol Ziemssen F, Bartz-Schmidt KU, Dimopoulos S (2016) Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when? Graefes Arch Clin Exp Ophthalmol
64.
Zurück zum Zitat Stalmans P (2016) A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit). Graefes Arch Clin Exp Ophthalmol Stalmans P (2016) A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit). Graefes Arch Clin Exp Ophthalmol
Metadaten
Titel
Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications
verfasst von
Irini Chatziralli
George Theodossiadis
Paraskevi Xanthopoulou
Michael Miligkos
Sobha Sivaprasad
Panagiotis Theodossiadis
Publikationsdatum
30.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 7/2016
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3363-5

Weitere Artikel der Ausgabe 7/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 7/2016 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.